Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 1, 2010, Pages 49-53

  Kim, Moon Jung ^a,b   Han, Eui Seok ^b   Kim, Jaewoo ^c   Kim, Tae Woo ^b,d  

^a Kong Eye Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; NONHUMAN; RABBIT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTERIOR CHAMBER; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; CONJUNCTIVA; FEMALE; HALF-LIFE; INJECTIONS, INTRAOCULAR; OSMOLAR CONCENTRATION; RABBITS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77649281715     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0022     Document Type: Article

References (28)

1. Iliev, M.E., Domig, D., Wolf-Schnurrbursch, U., et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am. J. Ophthalmol. 142:1054-1056, 2006.
2. Avery, R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 26:352-354, 2006.
3. Yazdani, S., Hendi, K., and Pakravan, M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J. Glaucoma. 16:437-439, 2007.
4. Vatavuk, Z., Bencic, G., and Mandic, Z. Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur. J. Ophthalmol. 17:269-271, 2007.
5. Grisanti, S., Biester, S., Peters, S., et al. Intracameral bevacizumab for iris rubeosis. Am. J. Ophthalmol. 142:158-160, 2006.
6. Ip, M.S., Scott, I.U., Brown, G.C., et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 115:1837-1846, 2008.
7. Ranta, V.P., and Urtti, A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv. Drug Deliv. Rev. 58:1164-1181, 2006.
8. Kim, T.W., Lindsey, J.D., Aihara, M., et al. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest. Ophthalmol. Vis. Sci. 43:1809-1816, 2002.
9. Ambati, J Gragoudas, E.S., Miller, J.W., et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. 41:1186-1191, 2000.
10. Järvinen, T., Järvinen, K., and Urtti, A. Ocular absorption following topical delivery. Adv. Drug Deliv. Rev. 16:16, 1995.
11. Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. Bevacizumab plus irinotecan, fl uorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335-2242, 2004.
12. Kabbinavar, F.F., Schulz, J., McCleod, M., et al. Addition of bevacizumab to bolus fl uorouracil and leucovorin in fi rst-line meta-static colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 23:3697-3705, 2005.
13. Giantonio, B.J., Levy, D.E., O'Dwyer, P.J., et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fl uorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann. Oncol. 17:1399-1403, 2006.
14. Krohne, T.U., Eter, N., Holz, F.G., et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am. J. Ophthalmol. 146:508-512, 2008.
15. Bakri, S.J., Snyder, M.R., Reid, J.M., et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 114:855-859, 2007.
16. Wang, Y., Fei, D., Vanderlaan, M., et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 7:335-345, 2004.
17. Avery, R.L., Pearlman, J., Pieramici, D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 113:1695.e1-15, 2006.
18. Lu, J.F., Bruno, R., Eppler, S., et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol. 62:779-786, 2008.
19. Bakri, S.J., Snyder, M.R., Reid, J.M., et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 114:2179-2182, 2007.
20. Scappaticci, F.A., Skillings, J.R., Holden, S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 99:1232-1239, 2007.
21. Costa, R.A., Jorge, R., Calucci, D., et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest. Ophthalmol. Vis. Sci. 47:4569-4578, 2006.
22. Cleary, C.A., Jungkim, S., Ravikumar, K., et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6-and 9-month results. Eye. 22:82-86, 2008.
23. Bashshur, Z.F., Haddad, Z.A., Schakal, A., et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am. J. Ophthalmol. 145:249-256, 2008.
24. Rensch, F., Spandau, U.H., Schlichtenbrede, F., et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic. Surg. Lasers Imaging 39:182-185, 2008.
25. Mason, J.O., III, Nixon, P.A., and White, M.F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am. J. Ophthalmol. 142:685-688, 2006.
26. Arevalo, J.F., Wu, L., Sanchez, J.G., et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye. 23:117-123, 2009.
27. Batioglu, F., Astam, N., and Ozmert, E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int. Ophthalmol. 28:59-61, 2008.
28. Ferrara, D.C., Koizumi, H., and Spaide, R.F. Early bevacizumab treatment of central retinal vein occlusion. Am. J. Ophthalmol. 144:864-871, 2007.